News | October 24, 2025
Lupin launches authorized generic of Ravicti in US
The product is indicated for the chronic management of patients with Urea Cycle Disorders
The product is indicated for the chronic management of patients with Urea Cycle Disorders
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Subscribe To Our Newsletter & Stay Updated
